2023-09-19 06:58:00 ET
More on BeiGene, Novartis, etc.
- Sales Success Comes With Side Effects For Drug Maker BeiGene
- Novartis: Q2 Beats Expectations, But Still Pricey
- Novartis: Strong Growth And Continued Expansion For KISQALI
- Novartis shareholders approve 100% spinout of Sandoz unit
- EMA advisors recommend many new meds at latest meeting
- Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara
- Generic drug prices have dropped significantly since 2006 - report
- Novartis schedules Sandoz spinoff for October
For further details see:
BeiGene regains full rights to cancer therapy from Novartis